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Dear editor
Recently, we read with great interest the review by Collignon et al entitled “Triple-
negative breast cancer: treatment challenges and solutions”,1 which appeared in the 
last issue of Breast Cancer: Targets and Therapy. In this article, the authors extensively 
reviewed studies concerning the opportunity to identify triple negative breast carcinoma 
(TNBC) subtypes by newly proposed markers, taking into account their biological 
heterogeneity on the light of clinical implications.
It is well known that TNBC represents ~15% of all breast cancers and they are 
distinguished by the lack of expression of the estrogen and progesterone receptor 
using immunohistochemistry (IHC) and by the lack of overexpression and/or ampli-
fication of HER2 obtained using IHC and/or fluorescence in situ hybridization.1 The 
clinicopathological characteristics of this subtype include tumors of large size, highly 
undifferentiated, high proliferative index, central necrosis, multiple apoptotic cells, 
and high-positive lymph nodes.
However, utilizing gene expression profiling of TNBC, a luminal androgen receptor 
subtype has been identified among others.2 Moreover, a recent systematic meta-analysis 
of 19 different studies showed that the expression of androgen receptor (AR) is a favor-
able prognostic marker, providing the rationale for the development of a Phase II study 
with bicalutamide, a nonsteroidal antiandrogen in the treatment of metastatic TNBC-AR 
positive (NCT00468715).3 In relation to this hypothesized role of AR, we would report 
herein our previous immunohistochemical experience in a cohort of TNBC.4 In detail, 
we have found AR immunopositivity (IHC >10%) in 26.6% of TNBC cases; moreover, 
both univariate and multivariate analyses showed that AR is significantly associated with 
overall survival, representing an independent variable able to identify a TNBC subtype.4 
These data further confirm the significantly positive correlation between AR expression 
and favorable survival in TNBC patients since higher AR expression predicted a better 
relapse-free survival in patients with chemoresistant TNBC, as reported elsewhere.5
In light of the abovementioned studies, we fully agree with the suggestion of 
 Collignon et al1 regarding the block of AR pathway as promising approach in the 
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 treatment of patients with the luminal AR subtype of TNBC. 
In fact, this new targeted therapy shows potential advantages,6 
although more additional studies are needed to be validated 
in order to acquire a prognostic/predictive significance of 
AR in TNBC. However, the documented inverse correlation 
between low AR expression and high Ki67 rate has been 
significantly correlated with a shorter overall survival and 
a more aggressive disease in TNBC.4 Therefore, our data 
suggest that an immunohistochemical tissue approach by the 
combination of AR expression and Ki-67 status might be a 
useful prognostic marker in TNBC in order to subclassify 
the risk of these patients.
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Dear editor
Thank you for having shared with us your interesting experi-
ence concerning the determination of the androgen receptor 
status, the inverse correlation between KI67 and androgen 
receptor expression, and the potential prognostic implica-
tions. Your results are in line with previous work published 
in this field and further highlights that additional research in 
this subgroup of triple negative breast cancer is definitively 
needed. In particular, we hope that specific treatments will 
allow us to do a major step forward in the treatment of a 
subgroup of patients presenting with triple negative breast 
cancer. Unfortunately, the results currently available with 
antiandrogen therapy, although promising, represent rather 
a very small step forward. Further research is also needed 
in order to evaluate if standard immunohistochemistry 
techniques can be an alternative to androgen-related gene 
signatures for the identification of patients presenting better 
outcome after antiandrogen therapy.
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